

Anti-C5 [Eculizumab] Standard Size Ab00296-25.0

This antibody is a human IgG2/IgG4 hybrid.

NOT FOR THERAPEUTIC USE - This is a research-grade biosimilar.

Isotype and Format: Human IgG2/4, Kappa

Clone Number: Eculizumab

Alternative Name(s) of Target: Complement Component 5; CPAMD4; Complement protein C5; h5G1.1

UniProt Accession Number of Target Protein: P01031

Published Application(s): Block, ELISA, EM

Published Species Reactivity: Human

Immunogen: C5 is activated by C5 convertase into C5a, an anaphylatoxin, and C5b a component of the membrane attack complex.

Specificity: Binds human C5 centred in the MG7 domain, at an epitope spanning Lys-879 to Arg-885 (Jore et al. 2016) Polymorphisms at Arg-885 correlate with drug resistance. Eculizumab demonstrates no appreciable species cross-reactivity. It is highly species specific. with no appreciable activity against chimpanzee, baboon, rhesus or cynomolgous monkey, pig, rabbit, guinea pig, or rat complement

Application Notes: This antibody inhibits activation of C5. The human Fab version (Ab00296-10.6) of this antibody was used by Jore et al. (2016, PMID: 27018802) to determine the binding site of this antibody to C5.

Antibody First Published in: Rother et al. Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria. Nat Biotechnol. [PMID:17989688](#)

Note on publication: Describes development and characterisation of Eculizumab.

Product Form

Size: 200 µg Purified antibody.

Purification: Protein A affinity purified

Supplied In: PBS with 0.02% Proclin 300.

Storage Recommendation: Store at 4°C for up to 3 months. For longer storage, aliquot and store at -20°C.

Concentration: 1 mg/ml.

Important note – This product is for research use only. It is not intended for use in therapeutic or diagnostic

procedures for humans or animals.